



Infrastructure on Production and Characterization of
Nanomaterials, Biomaterials and Systems in Biomedicine

1^a Convocatoria de “Acceso competitivo” a NANBIOSIS de 2023

Acuerdo de Priorización de Solicitudes de Acceso a NANBIOSIS

por del Comité de Coordinación

NANBIOSIS ofrece acceso a sus servicios a todos los usuarios, nacionales e internacionales, que pueden provenir del sector público o privado, bajo las modalidades de “Acceso Abierto Competitivo” o “Acceso por Demanda”. Las solicitudes de acceso seleccionadas en el modo abierto y competitivo obtendrán prioridad en el acceso a la instalación frente a las solicitudes consideradas en “acceso por demanda”. Existen dos convocatorias anuales de acceso competitivo.

El proceso de evaluación de dichas solicitudes se lleva a cabo en tres fases:

- Fase interna: Revisión administrativa interna y consulta con las unidades sobre la viabilidad técnica de los accesos solicitados
- Fase externa: Evaluación por el Comité de Acceso
- Priorización de solicitudes en régimen de acceso competitivo por el Comité de Coordinación de NANBIOSIS

En el marco de la 1^a Convocatoria de Acceso Abierto y Competitivo a la ICTS NANBIOSIS en 2023, el Comité de Coordinación de NANBIOSIS, siguiendo la evaluación solicitudes y propuesta de priorización emitida por del Comité de Acceso, acuerda:

- Conceder acceso priorizado en “modo abierto y competitivo” a las solicitudes cuyo código de entrada se destaca con fondo verde en la tabla que se muestra a continuación
- Establecer un orden de prioridad de acceso de dichas solicitudes en modo competitivo, a cada una de las unidades de NANBIOSIS. (Ordenadas de mayor a menor prioridad en la siguiente tabla)
- Considerar como “accesos a demanda” los indicados en las solicitudes cuyo código de entrada tiene fondo blanco en la siguiente tabla. Los accesos derivados de las solicitudes a demanda solo se realizarán una vez cubiertos los “accesos competitivos”.

Priorización de Solicitudes de Acceso a NANBIOSIS

Unidad	Solicitud	Servicios
1	3187	U1-S1. Molecular cloning (On-site&Remote) OUTSTANDING, U1-S2. Bioproduction of proteins (On-site&Remote) OUTSTANDING, U1-S3: Protein purification (On- site&Remote) OUTSTANDING
1	3039	U1-S2. Bioproduction of proteins (On-site&Remote) OUTSTANDING, U1-S3: Protein purification (On- site&Remote) OUTSTANDING
1	3041	U1-S2. Bioproduction of proteins (On-site&Remote) OUTSTANDING, U1-S3: Protein purification (On- site&Remote) OUTSTANDING
1	3042	U1-S2. Bioproduction of proteins (On-site&Remote) OUTSTANDING, U1-S3: Protein purification (On- site&Remote) OUTSTANDING
1	3044	U1-S2. Bioproduction of proteins (On-site&Remote) OUTSTANDING, U1-S3: Protein purification (On- site&Remote) OUTSTANDING
1	3074	U1-S3: Protein purification (On-site&Remote) OUTSTANDING U1-S2. Bioproduction of proteins (On-site&Remote) OUTSTANDING, U1-S3: Protein purification (On- site&Remote) OUTSTANDING
1	3130	U1-S2. Bioproduction of proteins (On-site&Remote) OUTSTANDING
1	3174	OUTSTANDING
1	3024	U1-S3: Protein purification (On-site&Remote) OUTSTANDING
1	3043	U1-S2. Bioproduction of proteins (On-site&Remote) OUTSTANDING, U1-S3: Protein purification (On- site&Remote) OUTSTANDING
1	3045	U1-S2. Bioproduction of proteins (On-site&Remote) OUTSTANDING, U1-S3: Protein purification (On- site&Remote) OUTSTANDING
1	3137	OUTSTANDING
1	3139	U1-S3: Protein purification (On-site&Remote) OUTSTANDING
1	3140	U1-S3: Protein purification (On-site&Remote) OUTSTANDING

Unidad	Solicitud	Servicios
2	3186	U2-S7. Antibody purification (Remote) OUTSTANDING U2-S5. Monoclonal Antibody development (Remote) OUTSTANDING, U2-S6. Hybridoma cell culture antibody production (Remote) OUTSTANDING, U2-S7. Antibody purification (Remote) OUTSTANDING
2	2999	U2-S1. Scientific and technical support (Remote), U2-S8. Immunochemical methods development (Remote)
2	3183	OUTSTANDING
2	3184	U2-S5. Monoclonal Antibody development (Remote) OUTSTANDING, U2-S6. Hybridoma cell culture antibody production (Remote) OUTSTANDING, U2-S7. Antibody purification (Remote) OUTSTANDING
2	3185	U2-S6. Hybridoma cell culture antibody production (Remote) OUTSTANDING
2	3189	U2-S4. Polyclonal Antibody Production (Remote) OUTSTANDING
2	3188	U2-S2. Hapten synthesis (Remote) OUTSTANDING, U2-S3. Preparation of bioconjugates and molecular probes (Remote) OUTSTANDING, U2-S6. Hybridoma cell culture antibody production (Remote) OUTSTANDING, U2-S7. Antibody purification (Remote) OUTSTANDING
2	3190	OUTSTANDING
2	3191	U2-S5. Monoclonal Antibody development (Remote) OUTSTANDING

Unidad	Solicitud	Servicios	
3	3172	U3-S1. Synthesis of peptides and characterisation (On-site&Remote) OUTSTANDING	
3	3173	U3-S1. Synthesis of peptides and characterisation (On-site&Remote) OUTSTANDING	
3	3175	U3-S1. Synthesis of peptides and characterisation (On-site&Remote) OUTSTANDING, U3-S2. Modification of the peptides (On-site&Remote) OUTSTANDING, U3-S3. Special amino acids for peptide synthesis (Remote) OUTSTANDING	Unidades implicadas 3 y 20
3	3192	U3-S1. Synthesis of peptides and characterisation (On-site&Remote) OUTSTANDING	
3	3050	U3-S1. Synthesis of peptides and characterisation (On-site&Remote) OUTSTANDING	

Unidad	Solicitud	Servicios
6	3000	U6-S4. Analysis of particle size, concentration, and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
6	3001	U6-S4. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
6	3002	U6-S4. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
6	3003	U6-S4. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
6	3004	U6-S4. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
6	3008	U6-S4. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
6	3013	U6-S4. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
6	3014	U6-S1. Use of High-pressure laboratory-scale plant with 50, 100 and 300 m reactors for the processing of biomaterials. Processing of cytotoxic compounds when required. (Remote) OUTSTANDING, U6-S2. High-pressure phase analysis – solubility, emulsification OUTSTANDING, U6-S4. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
6	3019	U6-S4. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
6	3017	U6-S4. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
6	3020	U6-S4. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
6	3033	U6-S4. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
6	3034	U6-S4. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
6	3056	U6-S4. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
6	3069	U6-S4. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
6	3080	U6-S4. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
6	2993	U6-S4. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
6	2994	U6-S4. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
6	2997	U6-S4. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
6	3006	U6-S4. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING



Infrastructure on Production and Characterization of
Nanomaterials, Biomaterials and Systems in Biomedicine

6	3007	U6-S4. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
6	3009	U6-S4. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
6	3010	U6-S4. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
		U6-S1. Use of High-pressure laboratory-scale plant with 50, 100 and 300 m reactors to process biomaterials. Processing of cytotoxic compounds when required. (Remote) OUTSTANDING, U6-S4. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING, U6-S13. Detection of labelled nanoparticles and exosomes by fluorescence mode (On-site&Remote) OUTSTANDING
6	3011	U6-S4. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
6	3083	U6-S4. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING
6	3016	U6-S4. Analysis of particle size, concentration and Z-potential of nanoparticles (On-site&Remote) OUTSTANDING

Unidad	Solicitud	Servicios
7	3047	U7-S7. Photolithography and soft-lithography manufacturing processes (On-site&Remote) OUTSTANDING, U7-S8. Fabrication of Chromium masks (Remote) OUTSTANDING, U7-S10. Advising and consulting in micro and nanofabrication (On-site&Remote)
7	3075	U7-S1. Training Courses in the Use of nanotechnology equipment (Onsite), U7-S7. Photolithography and soft-lithography manufacturing processes (On-site&Remote) OUTSTANDING
7	3025	U7-S7. Photolithography and soft-lithography manufacturing processes (On-site&Remote) OUTSTANDING
7	3040	U7-S7. Photolithography and soft-lithography manufacturing processes (On-site&Remote) OUTSTANDING
7	3171	U7-S1. Training Courses in the Use of nanotechnology equipment (Onsite)
7	3199	U7-S1. Training Courses in the Use of nanotechnology equipment (Onsite), U7-S10. Advising and consulting in micro and nanofabrication (On-site&Remote)
7	3125	U7-S3. Characterization by SEM (On-site&Remote) OUTSTANDING

Unidad	Solicitud	Servicios
8	3105	U8-S01. Design, fabrication and encapsulation of microelectrodes (based on gold or platinum) on different rigid (Si, SiC or Pyrex) or flexible polymeric substrates (On-site&Remote) OUTSTANDING, U8-S02. Electrochemical and electrical characterization of the above-mentioned microelectrodes (On-site&Remote) OUTSTANDING, U8-S04. Graphene growth services (On-site&Remote) OUTSTANDING



Infrastructure on Production and Characterization of
Nanomaterials, Biomaterials and Systems in Biomedicine

8	3106	U8-S01. Design, fabrication and encapsulation of microelectrodes (based on gold or platinum) on different rigid (Si, SiC or Pyrex) or flexible polymeric substrates (On-site&Remote) OUTSTANDING, U8-S02. Electrochemical and electrical characterization of the above-mentioned microelectrodes (On-site&Remote) OUTSTANDING, U8-S04. Graphene growth services (On-site&Remote) OUTSTANDING, U8-S05 Deposition of thin films (Polyimide, Parylene) for the fabrication of flexible devices or encapsulation purposes (On-site&Remote) OUTSTANDING, U8-S06 Encapsulation or fabrication of 3D structures via 3D printing
8	3021	U8-S05 Deposition of thin films (Polyimide, Parylene) for the fabrication of flexible devices or encapsulation purposes (On-site&Remote) OUTSTANDING
8	3046	U8-S05 Deposition of thin films (Polyimide, Parylene) for the fabrication of flexible devices or encapsulation purposes (On-site&Remote) OUTSTANDING
8	3110	U8-S01. Design, fabrication and encapsulation of microelectrodes (based on gold or platinum) on different rigid (Si, SiC or Pyrex) or flexible polymeric substrates (On-site&Remote) OUTSTANDING
8	3117	U8-S06 Encapsulation or fabrication of 3D structures via 3D printing

Unidad	Solicitud	Servicios
10	3032	U10-S03. Design & Development of solid lipid nanoparticles (SLN) (Remote) OUTSTANDING
10	3038	U10-S01. Design & Development of pharmaceutical forms (Remote) OUTSTANDING, U10-S02. Design & Development of micro- & nanocapsules (Remote) OUTSTANDING, U10-S06. Setup and validation of analytical techniques (Remote) OUTSTANDING, U10-S07. Pharmacokinetic pre-clinical studies (Remote) OUTSTANDING
10	3055	U10-S09. Characterization and development of pulmonary formulations (On-site&Remote) OUTSTANDING
10	3057	U10-S08. 3D bio-impression of scaffolding for regenerative medicine (On-site&Remote) OUTSTANDING
10	3054	U10-S09. Characterization and development of pulmonary formulations (On-site&Remote) OUTSTANDING

Unidad	Solicitud	Servicios
12	3152	U12-S01. Characterization of colloidal dispersions by Dynamic and Static Light Scattering (DLS and SLS) and Light Diffraction (Remote) OUTSTANDING, U12-S03. Determination of the phase behaviour of surfactant and polymers systems (Remote) OUTSTANDING, U12-S04. Rheology, viscometry and densimetry (Remote) OUTSTANDING, U12-S05. Surface and interfacial tensiometry (Remote) OUTSTANDING, U12-S07. Evaluation of colloidal stability (Remote) OUTSTANDING, U12-S08. Characterization of materials by high resolution optical microscopy with spectral analysis and scanning electron microscopy (Remote) OUTSTANDING
12	3153	U12-S03. Determination of the phase behaviour of surfactant and polymers systems (Remote) OUTSTANDING, U12-S08. Characterization of materials by high resolution optical microscopy with spectral analysis and scanning electron microscopy (Remote) OUTSTANDING
12	3127	U12-S04. Rheology, viscometry and densimetry (Remote) OUTSTANDING

12	3146	U12-S06. Contact angle and wettability (Remote) OUTSTANDING, U12-S08. Characterization of materials by high resolution optical microscopy with spectral analysis and scanning electron microscopy (Remote) OUTSTANDING
12	3163	U12-S01. Characterization of colloidal dispersions by Dynamic and Static Light Scattering (DLS and SLS) and Light Diffraction (Remote) OUTSTANDING, U12-S04. Rheology, viscometry and densimetry (Remote) OUTSTANDING, U12-S07. Evaluation of colloidal stability (Remote) OUTSTANDING

Unidad	Solicitud	Servicios
13	3200	U13-S05. UNIAXIAL TENSILE TEST INSTRON Micro Tester (Remote) OUTSTANDING, U13-S06. CONFINED COMPRESSION TEST INSTRON Micro Tester (Remote) OUTSTANDING
13	3202	U13-S04. DYNAMIC MECHANICAL ANALYSIS INSTRON 8874 (Remote) OUTSTANDING, U13-S05. UNIAXIAL TENSILE TEST INSTRON Micro Tester (Remote) OUTSTANDING, U13-S06. CONFINED COMPRESSION TEST INSTRON Micro Tester (Remote) OUTSTANDING
13	3204	U13-S04. DYNAMIC MECHANICAL ANALYSIS INSTRON 8874 (Remote) OUTSTANDING, U13-S05. UNIAXIAL TENSILE TEST INSTRON Micro Tester (Remote) OUTSTANDING, U13-S06. CONFINED COMPRESSION TEST INSTRON Micro Tester (Remote) OUTSTANDING
13	3206	U13-S04. DYNAMIC MECHANICAL ANALYSIS INSTRON 8874 (Remote) OUTSTANDING, U13-S05. UNIAXIAL TENSILE TEST INSTRON Micro Tester (Remote) OUTSTANDING, U13-S06. CONFINED COMPRESSION TEST INSTRON Micro Tester (Remote) OUTSTANDING
13	3208	U13-S04. DYNAMIC MECHANICAL ANALYSIS INSTRON 8874 (Remote) OUTSTANDING, U13-S05. UNIAXIAL TENSILE TEST INSTRON Micro Tester (Remote) OUTSTANDING, U13-S06. CONFINED COMPRESSION TEST INSTRON Micro Tester (Remote) OUTSTANDING
13	3036	U13-S04. DYNAMIC MECHANICAL ANALYSIS INSTRON 8874 (Remote) OUTSTANDING, U13-S05. UNIAXIAL TENSILE TEST INSTRON Micro Tester (Remote) OUTSTANDING, U13-S06. CONFINED COMPRESSION TEST INSTRON Micro Tester (Remote) OUTSTANDING
13	3210	U13-S04. DYNAMIC MECHANICAL ANALYSIS INSTRON 8874 (Remote) OUTSTANDING, U13-S05. UNIAXIAL TENSILE TEST INSTRON Micro Tester (Remote) OUTSTANDING, U13-S06. CONFINED COMPRESSION TEST INSTRON Micro Tester (Remote) OUTSTANDING

Unidad	Solicitud	Servicios	Unidades implicadas
14	3089	U14-S01. Cell cultures (Onsite&Remote) OUTSTANDING	Unidades implicadas 14, 21, 22, 24
14	3128	U14-S01. Cell cultures (Onsite&Remote) OUTSTANDING	Unidades implicadas 14, 19, 21, 22, 24
14	3170	U14-S01. Cell cultures (Onsite&Remote) OUTSTANDING, U14-S02. Flow Cytometry (Onsite&Remote) OUTSTANDING, U14-S4. Cytokine quantification assays (On-site&Remote) OUTSTANDING, U14-S5. Determination of cytokine concentration by flow cytometry (On-site&Remote) OUTSTANDING, U14-S6. Lymphocyte proliferation assay (On-site&Remote) OUTSTANDING	Unidades implicadas 14, 19, 21, 22, 24
14	3112	U14-S01. Cell cultures (Onsite&Remote) OUTSTANDING, U14-S02. Flow Cytometry (Onsite&Remote) OUTSTANDING, U14-S4. Cytokine quantification assays (On-site&Remote) OUTSTANDING	Unidades implicadas 14, 19, 21, 22, 24

14	3167	U14-S01. Cell cultures (Onsite&Remote) OUTSTANDING, U14-S02. Flow Cytometry (Onsite&Remote) OUTSTANDING, U14-S4. Cytokine quantification assays (On-site&Remote) OUTSTANDING, U14-S5. Determination of cytokine concentration by flow cytometry (On-site&Remote) OUTSTANDING, U14-S6. Lymphocyte proliferation assay (On- site&Remote) OUTSTANDING
14	3168	U14-S01. Cell cultures (Onsite&Remote) OUTSTANDING, U14-S02. Flow Cytometry (Onsite&Remote) OUTSTANDING, U14-S4. Cytokine quantification assays (On-site&Remote) OUTSTANDING, U14-S5. Determination of cytokine concentration by flow cytometry (On-site&Remote) OUTSTANDING, U14-S6. Lymphocyte proliferation assay (On- site&Remote) OUTSTANDING
14	3169	U14-S01. Cell cultures (Onsite&Remote) OUTSTANDING, U14-S02. Flow Cytometry (Onsite&Remote) OUTSTANDING, U14-S4. Cytokine quantification assays (On-site&Remote) OUTSTANDING, U14-S5. Determination of cytokine concentration by flow cytometry (On-site&Remote) OUTSTANDING, U14-S6. Lymphocyte proliferation assay (On- site&Remote) OUTSTANDING

Unidad	Solicitud	Servicios
16	3053	U16-S05. DROP SHAPE ANALYZER – DSA100E – Goniometer- (Remote) OUTSTANDING, U16-S06. 3D Optical Surface Metrology System Leica DCM8 – Optical profilometer- (Remote) OUTSTANDING, U16-S08. Evaluation in percentages of the elemental composition of surfaces -except H and He-, even with deep profiling
16	3134	U16-S08. Evaluation in percentages of the elemental composition of surfaces -except H and He-, even with deep profiling
16	3135	U16-S08. Evaluation in percentages of the elemental composition of surfaces -except H and He-, even with deep profiling
16	3136	U16-S08. Evaluation in percentages of the elemental composition of surfaces -except H and He-, even with deep profiling

Unidad	Solicitud	Servicios
17	3102	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING
17	3058	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING
17	3071	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING
17	3072	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING
17	3073	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING
17	3076	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING
17	3079	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING
17	3087	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING
17	3095	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING
17	3107	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING
17	3113	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING

17	3165	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING
17	3101	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING
17	3104	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING
17	3062	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING
17	3086	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING
17	3129	U17-S01. Confocal Microscopy Service (Onsite) OUTSTANDING

Unidad	Solicitud	Servicios
18	3150	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING, U18-S03. In vivo TOXICOLOGY (Onsite&Remote) OUTSTANDING
18	3154	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING, U18-S03. In vivo TOXICOLOGY (Onsite&Remote) OUTSTANDING
18	3155	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING, U18-S03. In vivo TOXICOLOGY (Onsite&Remote) OUTSTANDING
18	3156	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING, U18-S03. In vivo TOXICOLOGY (Onsite&Remote) OUTSTANDING
18	3157	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING, U18-S03. In vivo TOXICOLOGY (Onsite&Remote) OUTSTANDING
18	3158	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING, U18-S03. In vivo TOXICOLOGY (Onsite&Remote) OUTSTANDING
18	3159	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING, U18-S03. In vivo TOXICOLOGY (Onsite&Remote) OUTSTANDING
18	3160	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING, U18-S03. In vivo TOXICOLOGY (Onsite&Remote) OUTSTANDING
18	3161	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING, U18-S03. In vivo TOXICOLOGY (Onsite&Remote) OUTSTANDING
18	3162	U18-S02. IN VIVO NANOTOXICOLOGY, preclinical histopathology in animal models (Remote) OUTSTANDING, U18-S03. In vivo TOXICOLOGY (Onsite&Remote) OUTSTANDING

Unidad	Solicitud	Servicios	
19	3128	U19-S03. Clinical Analysis Laboratory (On-site&Remote) OUTSTANDING	Unidades implicadas 14, 21, 22, 24
19	3166	U19-S01. Preclinical Studies (Onsite&Remote) OUTSTANDING, U19-S03. Clinical Analysis Laboratory (On-site&Remote) OUTSTANDING	Unidades implicadas 19, 21, 22, 24

19	3170	U19-S01. Preclinical Studies (Onsite&Remote) OUTSTANDING, U19-S02. Animal Model Studies (Onsite&Remote) OUTSTANDING, U19-S03. Clinical Analysis Laboratory (On-site&Remote) OUTSTANDING, U19-S04. Magistral formulation (Remote)	Unidades implicadas 14, 19, 21, 22, 24
19	3112	U19-S01. Preclinical Studies (Onsite&Remote) OUTSTANDING, U19-S02. Animal Model Studies (Onsite&Remote) OUTSTANDING, U19-S03. Clinical Analysis Laboratory (On-site&Remote) OUTSTANDING	Unidades implicadas 14, 19, 21, 22, 24
19	3167	U19-S01. Preclinical Studies (Onsite&Remote) OUTSTANDING, U19-S02. Animal Model Studies (Onsite&Remote) OUTSTANDING, U19-S03. Clinical Analysis Laboratory (On-site&Remote) OUTSTANDING	Unidades implicadas 14, 19, 21, 22, 24

Unidad	Solicitud	Servicios	
20	2996	U20-S01. Non-invasive optical imaging (bioluminescence and fluorescence) (Remote) OUTSTANDING U20-S11. Histological processing, section and staining (Remote) OUTSTANDING	
20	3023	U20-S11. Histological processing, section and staining (Remote) OUTSTANDING	
20	3031	U20-S11. Histological processing, section and staining (Remote) OUTSTANDING	
20	3037	U20-S01. Non-invasive optical imaging (bioluminescence and fluorescence) (Remote) OUTSTANDING, U20-S03. In vivo Experimental consultancy (Remote) OUTSTANDING, U20-S04. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING, U20-S05. In vivo Toxicology (Onsite&Remote) OUTSTANDING, U20-S06. In vivo ADME and biodistribution assays (Remote) OUTSTANDING, U20-S11. Histological processing, section and staining (Remote) OUTSTANDING, U20-S12. Immunohistochemistry on histological samples (Remote) OUTSTANDING, U20-S013. Detection of microbial (bacterial and mycoplasma) contamination	
20	3145	U20-S01. Non-invasive optical imaging (bioluminescence and fluorescence) (Remote) OUTSTANDING, U20-S06. In vivo ADME and biodistribution assays (Remote) OUTSTANDING	
20	3175	U20-S01. Non-invasive optical imaging (bioluminescence and fluorescence) (Remote) OUTSTANDING, U20-S02. Animal models in oncology (Remote) OUTSTANDING, U20-S03. In vivo Experimental consultancy (Remote) OUTSTANDING, U20-S04. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING, U20-S05. In vivo Toxicology (Onsite&Remote) OUTSTANDING, U20-S06. In vivo ADME and biodistribution assays (Remote) OUTSTANDING, U20-S11. Histological processing, section and staining (Remote) OUTSTANDING, U20-S12. Immunohistochemistry on histological samples (Remote) OUTSTANDING	Unidades implicadas 3 y 20
20	3178	U20-S01. Non-invasive optical imaging (bioluminescence and fluorescence) (Remote) OUTSTANDING, U20-S03. In vivo Experimental consultancy (Remote) OUTSTANDING, U20-S04. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING, U20-S05. In vivo Toxicology (Onsite&Remote) OUTSTANDING, U20-S06. In vivo ADME and biodistribution assays (Remote) OUTSTANDING, U20-S11. Histological processing, section and staining (Remote) OUTSTANDING, U20-S12. Immunohistochemistry on histological samples (Remote) OUTSTANDING	
20	3182	U20-S01. Non-invasive optical imaging (bioluminescence and fluorescence) (Remote) OUTSTANDING	
20	2995	U20-S01. Non-invasive optical imaging (bioluminescence and fluorescence) (Remote) OUTSTANDING	

20	3048	U20-S01. Non-invasive optical imaging (bioluminescence and fluorescence) (Remote) OUTSTANDING
20	3049	U20-S01. Non-invasive optical imaging (bioluminescence and fluorescence) (Remote) OUTSTANDING, U20-S02. Animal models in oncology (Remote) OUTSTANDING
20	3070	U20-S01. Non-invasive optical imaging (bioluminescence and fluorescence) (Remote) OUTSTANDING
20	3124	U20-S11. Histological processing, section and staining (Remote) OUTSTANDING, U20-S12. Immunohistochemistry on histological samples (Remote) OUTSTANDING
20	3126	U20-S01. Non-invasive optical imaging (bioluminescence and fluorescence) (Remote) OUTSTANDING
20	3131	U20-S015. Cytotoxicity: proliferation, LDH, apoptosis and ROS
20	3179	U20-S01. Non-invasive optical imaging (bioluminescence and fluorescence) (Remote) OUTSTANDING

Unidad	Solicitud	Servicios	
21	3089	U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING	Unidades implicadas 14, 21, 22, 24
21	3122	U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING	Unidades implicadas 21, 22, 24
21	3128	U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING	Unidades implicadas 14, 21, 22, 24
21	3166	U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING	Unidades implicadas 19, 21, 22, 24
21	3170	U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING	Unidades implicadas 14, 19, 21, 22, 24
21	3181	U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING	Unidades implicadas 21, 22, 24
21	3112	U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING	Unidades implicadas 14, 19, 21, 22, 24
21	3167	U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING	Unidades implicadas 14, 19, 21, 22, 24

Unidad	Solicitud	Servicios	
22	3094	U22-S01. Animal Housing (Remote) OUTSTANDING	
22	3089	U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S02. In vivo experimental design/consultancy for preclinical studies (On-site&Remote)	Unidades implicadas 14, 21, 22, 24
22	3122	U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S02. In vivo experimental design/consultancy for preclinical studies (On-site&Remote), U22-S06. In vivo safety and efficacy studies of nanomaterials, biomaterials and new drugs in rodent and non-rodent species (On-site) OUTSTANDING	Unidades implicadas 21, 22, 24
22	3128	U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S06. In vivo safety and efficacy studies of nanomaterials, biomaterials and new drugs in rodent and non-rodent species (On-site) OUTSTANDING, U22-S07. Development of animal models of disease in large animals (On-site) OUTSTANDING	Unidades implicadas 14, 21, 22, 24
22	3166	U22-S01. Animal Housing (Remote) OUTSTANDING	Unidades implicadas 19, 21, 22, 24
22	3170	U22-S01. Animal Housing (Remote) OUTSTANDING	Unidades implicadas 14, 19, 21, 22, 24
22	3181	U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S06. In vivo safety and efficacy studies of nanomaterials, biomaterials and new drugs in rodent and non-rodent species (On-site) OUTSTANDING, U22-S07. Development of animal models of disease in large animals (On-site) OUTSTANDING	Unidades implicadas 21, 22, 24

		U22-S01. Animal Housing (Remote) OUTSTANDING, U22-S02. In vivo experimental design/consultancy for preclinical studies (On-site&Remote), U22-S03. In vivo toxicology in rodent and non-rodent species (On-site), U22-S04. In vivo biocompatibility studies of medical devices in rodent and non-rodent species (On-site), U22-S05. In vivo PK/PD assays in rodent and non-rodent species (On-site), U22-S06. In vivo safety and efficacy studies of nanomaterials, biomaterials and new drugs in rodent and non-rodent species (On-site) OUTSTANDING, U22-S07. Development of animal models of disease in large animals (On-site) OUTSTANDING, U22-S08. Dosing of test substances and non-clinical specimen drawing in rodent and non-rodent species (On-site) OUTSTANDING	Unidades implicadas 14, 19, 21, 22, 24
22	3112	U22-S01. Animal Housing (Remote) OUTSTANDING	Unidades implicadas 14, 19, 21, 22, 24

Unidad	Solicitud	Servicios	
24	3089	U24-S01. Evaluation of therapies for cardiovascular disease	Unidades implicadas 14, 21, 22, 24
24	3122	U24-S02. Medical Imaging for Minimal Invasive Surgery	Unidades implicadas 21, 22, 24
24	3128	U24-S01. Evaluation of therapies for cardiovascular disease	Unidades implicadas 14, 21, 22, 24
24	3166	U24-S02. Medical Imaging for Minimal Invasive Surgery	Unidades implicadas 19, 21, 22, 24
24	3181		
24	3170	U24-S01. Evaluation of therapies for cardiovascular disease, U24-S02. Medical Imaging for Minimal Invasive Surgery	Unidades implicadas 14, 19, 21, 22, 24
24	3112	U24-S01. Evaluation of therapies for cardiovascular disease, U24-S02. Medical Imaging for Minimal Invasive Surgery	Unidades implicadas 14, 19, 21, 22, 24
24	3167	U24-S01. Evaluation of therapies for cardiovascular disease, U24-S02. Medical Imaging for Minimal Invasive Surgery	Unidades implicadas 14, 19, 21, 22, 24

Unidad	Solicitud	Servicios	
25	3077	U25-S05. Preclinical horizontal spectrometer Biospec 7T (Onsite&Remote) OUTSTANDING	
25	3081	U25-S05. Preclinical horizontal spectrometer Biospec 7T (Onsite&Remote) OUTSTANDING	
25	3082	U25-S05. Preclinical horizontal spectrometer Biospec 7T (Onsite&Remote) OUTSTANDING	
25	3111	U25-S02. NMR spectrometer 500MHz/600MHz (Onsite&Remote) OUTSTANDING	
25	3164	U25-S05. Preclinical horizontal spectrometer Biospec 7T (Onsite&Remote) OUTSTANDING	
25	3096	U25-S01. NMR spectrometer 250MHz robot/250MHz auto/360MHz/400MHz (Onsite&Remote) OUTSTANDING, U25-S02. NMR spectrometer 500MHz/600MHz (Onsite&Remote) OUTSTANDING, U25-S03. NMR spectrometer 400 MHz with HRMAS/CPMAS probes (Onsite&Remote) OUTSTANDING, U25-S04. 500 MHz spectrometer HPLC-NMR(Onsite&Remote) OUTSTANDING	

Unidad	Solicitud	Servicios	
26	3084	U26-S01. Acquisition of mono and bidimensional spectra (On-site&Remote) OUTSTANDING	
26	3098	U26-S02. NMR experiments in solid state (Remote) OUTSTANDING	
26	3121	U26-S02. NMR experiments in solid state (Remote) OUTSTANDING	
26	3123	U26-S06. Biomedical and metabolomic imaging (On-site)	

26	3193	U26-S02. NMR experiments in solid state (Remote) OUTSTANDING
26	3018	U26-S06. Biomedical and metabolomic imaging (On-site)
26	3026	U26-S01. Acquisition of mono and bidimensional spectra (On-site&Remote) OUTSTANDING
26	3067	U26-S01. Acquisition of mono and bidimensional spectra (On-site&Remote) OUTSTANDING
26	3068	U26-S01. Acquisition of mono and bidimensional spectra (On-site&Remote) OUTSTANDING
26	3078	U26-S01. Acquisition of mono and bidimensional spectra (On-site&Remote) OUTSTANDING
26	3097	U26-S01. Acquisition of mono and bidimensional spectra (On-site&Remote) OUTSTANDING
26	3194	U26-S06. Biomedical and metabolomic imaging (On-site) U26-S02. NMR experiments in solid state (Remote) OUTSTANDING
26	3099	U26-S02. NMR experiments in solid state (Remote) OUTSTANDING
26	3103	U26-S02. NMR experiments in solid state (Remote) OUTSTANDING

Unidad	Solicitud	Servicios
27	3138	U27-S01. Remote access to HPC (On-site&Remote), U27-S03. Biomedical signals processing, especially in cardiology (Onsite&Remote) OUTSTANDING
27	3141	U27-S01. Remote access to HPC (On-site&Remote), U27-S03. Biomedical signals processing, especially in cardiology (Onsite&Remote) OUTSTANDING
27	3142	U27-S03. Biomedical signals processing, especially in cardiology (Onsite&Remote) OUTSTANDING, U27-S04. Modelling of the functional behaviour of tissues and organs (Onsite&Remote) OUTSTANDING
27	3143	U27-S03. Biomedical signals processing, especially in cardiology (Onsite&Remote) OUTSTANDING
27	3144	U27-S03. Biomedical signals processing, especially in cardiology (Onsite&Remote) OUTSTANDING, U27-S04. Modelling of the functional behaviour of tissues and organs (Onsite&Remote) OUTSTANDING
27	3148	U27-S03. Biomedical signals processing, especially in cardiology (Onsite&Remote) OUTSTANDING, U27-S04. Modelling of the functional behaviour of tissues and organs (Onsite&Remote) OUTSTANDING
27	3151	U27-S01. Remote access to HPC (On-site&Remote), U27-S06.
27	3176	Mass storage (Onsite&Remote)
27	3195	U27-S01. Remote access to HPC (On-site&Remote) U27-S01. Remote access to HPC (On-site&Remote), U27-S03. Biomedical signals processing, especially in cardiology (Onsite&Remote) OUTSTANDING
27	3201	U27-S02. Software installation on demand (Onsite&Remote) OUTSTANDING, U27-S04. Modelling of the functional behaviour of tissues and organs (Onsite&Remote) OUTSTANDING, U27-S06. Mass storage (Onsite&Remote)
27	3203	U27-S02. Software installation on demand (Onsite&Remote) OUTSTANDING, U27-S04. Modelling of the functional behaviour of tissues and organs (Onsite&Remote) OUTSTANDING, U27-S06. Mass storage (Onsite&Remote)
27	3205	U27-S02. Software installation on demand (Onsite&Remote) OUTSTANDING, U27-S04. Modelling of the functional behaviour of tissues and organs (Onsite&Remote) OUTSTANDING, U27-S06. Mass storage (Onsite&Remote)

			U27-S02. Software installation on demand (Onsite&Remote) OUTSTANDING, U27-S04. Modelling of the functional behaviour of tissues and organs (Onsite&Remote) OUTSTANDING, U27-S06. Mass storage (Onsite&Remote)
27	3207		U27-S02. Software installation on demand (Onsite&Remote) OUTSTANDING, U27-S04. Modelling of the functional behaviour of tissues and organs (Onsite&Remote) OUTSTANDING, U27-S06. Mass storage (Onsite&Remote)
27	3209		U27-S01. Remote access to HPC (On-site&Remote)
27	3211		U27-S02. Software installation on demand (Onsite&Remote) OUTSTANDING, U27-S04. Modelling of the functional behaviour of tissues and organs (Onsite&Remote) OUTSTANDING, U27-S06. Mass storage (Onsite&Remote)
27	3212		U27-S03. Biomedical signals processing, especially in cardiology (Onsite&Remote) OUTSTANDING
27	3177		U27-S03. Biomedical signals processing, especially in cardiology (Onsite&Remote) OUTSTANDING
27	3180		U27-S01. Remote access to HPC (On-site&Remote), U27-S03. Biomedical signals processing, especially in cardiology (Onsite&Remote) OUTSTANDING, U27-S06. Mass storage
27	3196		(Onsite&Remote)
27	3198		U27-S01. Remote access to HPC (On-site&Remote)

Unidad	Solicitud	Servicios
28	3085	U28-S04. High Resolution Liquid NMR (Onsite&Remote) OUTSTANDING, U28-S07. Transmission Electron Microscopy (TEM) (Onsite&Remote), U28-S017. Multiphoton Microscopy (Onsite&Remote) OUTSTANDING
28	3091	U28-S07. Transmission Electron Microscopy (TEM) (Onsite&Remote)
28	3092	U28-S04. High Resolution Liquid NMR (Onsite&Remote) OUTSTANDING, U28-S07. Transmission Electron Microscopy (TEM) (Onsite&Remote) U28-S02. Fluorescent and Bioluminescent Optical Imaging (Onsite&Remote) OUTSTANDING, U28-S07. Transmission Electron Microscopy (TEM) (Onsite&Remote), U28-S010. Scanning Electron Microscopy (SEM) (Onsite&Remote), U28-S016. Confocal Microscopy (Onsite&Remote) OUTSTANDING, U28-S017. Multiphoton Microscopy (Onsite&Remote) OUTSTANDING, U28-S019. Fluorescence microscopy (Onsite&Remote), U28-S021. Flow Cytometry/Cell Sorter (Onsite&Remote)
28	3093	U28-S01. Magnetic Resonance Imaging (MRI) (Onsite&Remote) OUTSTANDING, U28-S02. Fluorescent and Bioluminescent Optical Imaging (Onsite&Remote) OUTSTANDING, U28-S03. Computed Tomography (CT) (Onsite&Remote), U28-S04. High Resolution Liquid NMR (Onsite&Remote) OUTSTANDING, U28-S05. High Resolution Magic Angle Spinning (HR-MAS) NMR (Onsite&Remote), U28-S016. Confocal Microscopy (Onsite&Remote) OUTSTANDING, U28-S020. High Content Screening (Onsite&Remote) OUTSTANDING
28	3119	OUTSTANDING



Infrastructure on Production and Characterization of
Nanomaterials, Biomaterials and Systems in Biomedicine

28	3147	U28-S01. Magnetic Resonance Imaging (MRI) (Onsite&Remote) OUTSTANDING, U28-S04. High Resolution Liquid NMR (Onsite&Remote) OUTSTANDING, U28-S07. Transmission Electron Microscopy (TEM) (Onsite&Remote), U28-S010. Scanning Electron Microscopy (SEM) (Onsite&Remote), U28-S016. Confocal Microscopy (Onsite&Remote) OUTSTANDING, U28-S017. Multiphoton Microscopy (Onsite&Remote) OUTSTANDING, U28-S019. Fluorescence microscopy (Onsite&Remote), U28-S020. High Content Screening (Onsite&Remote) OUTSTANDING, U28-S021. Flow Cytometry/Cell Sorter (Onsite&Remote)	
28	3149	U28-S01. Magnetic Resonance Imaging (MRI) (Onsite&Remote) OUTSTANDING, U28-S04. High-Resolution Liquid NMR (Onsite&Remote) OUTSTANDING, U28-S016. Confocal Microscopy (Onsite&Remote) OUTSTANDING, U28-S019. Fluorescence microscopy (Onsite&Remote), U28-S020. High Content Screening (Onsite&Remote) OUTSTANDING, U28-S021. Flow Cytometry/Cell Sorter (Onsite&Remote)	
28	3061	U28-S019. Fluorescence microscopy (Onsite&Remote)	
28	3090	U28-S04. High Resolution Liquid NMR (Onsite&Remote) OUTSTANDING, U28-S07. Transmission Electron Microscopy (TEM) (Onsite&Remote), U28-S010. Scanning Electron Microscopy (SEM) (Onsite&Remote)	
28	3115	U28-S01. Magnetic Resonance Imaging (MRI) (Onsite&Remote) OUTSTANDING, U28-S03. Computed Tomography (CT) (Onsite&Remote), U28-S06. Time Domain NMR (TD-NMR) (Onsite&Remote) U28-S01. Magnetic Resonance Imaging (MRI) (Onsite&Remote) OUTSTANDING, U28-S07. Transmission Electron Microscopy (TEM) (Onsite&Remote), U28-S016. Confocal Microscopy (Onsite&Remote) OUTSTANDING, U28-S020. High Content Screening (Onsite&Remote)	
28	3118	OUTSTANDING U28-S01. Magnetic Resonance Imaging (MRI) (Onsite&Remote) OUTSTANDING, U28-S02. Fluorescent and Bioluminescent Optical Imaging (Onsite&Remote) OUTSTANDING, U28-S05. High Resolution Magic Angle Spinning (HR-MAS) NMR (Onsite&Remote), U28-S020. High Content Screening (Onsite&Remote) OUTSTANDING	
28	3120	Content Screening (Onsite&Remote) OUTSTANDING	

Unidad	Solicitud	Servicios
29	3030	U29-S01. Synthesis of oligonucleotides and characterization (On-site & Remote). OUTSTANDING, U29-S02. Modification of oligonucleotides. (Remote) OUTSTANDING U29-S01. Synthesis of oligonucleotides and characterization (On-site & Remote). OUTSTANDING, U29-S02. Modification of oligonucleotides. (Remote) OUTSTANDING
29	3035	U29-S02. Modification of oligonucleotides. (Remote) OUTSTANDING
29	3060	U29-S02. Modification of oligonucleotides. (Remote) OUTSTANDING
29	3064	U29-S02. Modification of oligonucleotides. (Remote) OUTSTANDING
29	3065	U29-S02. Modification of oligonucleotides. (Remote) OUTSTANDING
29	3066	U29-S02. Modification of oligonucleotides. (Remote) OUTSTANDING

Unidad	Solicitud	Servicios
30	3005	U30-S01. Sample preparation for proteomic analysis, U30-S04. Quantitative shotgun proteomics by nLC-MS/MS, U30-S09. Data analysis of proteomics experiments
30	3213	U30-S08. Luminex or ELISA assay development and analysis



Infrastructure on Production and Characterization of
Nanomaterials, Biomaterials and Systems in Biomedicine

30	3215	U30-S01. Sample preparation for proteomic analysis, U30-S04. Quantitative shotgun proteomics by nLC-MS/MS, U30-S05. Targeted proteomics analysis by MRM or PRM-MS, U30-S08. Luminex or ELISA assay development and analysis, U30-S09. Data analysis of proteomics experiments
30	3116	U30-S01. Sample preparation for proteomic analysis, U30-S04. Quantitative shotgun proteomics by nLC-MS/MS, U30-S09. Data analysis of proteomics experiments
30	3214	U30-S01. Sample preparation for proteomic analysis, U30-S04. Quantitative shotgun proteomics by nLC-MS/MS, U30-S09. Data analysis of proteomics experiments
30	2998	U30-S01. Sample preparation for proteomic analysis, U30-S04. Quantitative shotgun proteomics by nLC-MS/MS, U30-S09. Data analysis of proteomics experiments
30	3114	U30-S03. Protein identification by mass spectrometry (MS) or MS/MS
30	3197	U30-S08. Luminex or ELISA assay development and analysis

15 de marzo de 2023
Comité de Coordinación de NANBIOSIS